High level expression and purification of therapeutic human and mouse neuroserpin

Award Information
Agency:
Department of Health and Human Services
Amount:
$116,835.00
Program:
SBIR
Contract:
1R43NS056510-01A2
Solitcitation Year:
2008
Solicitation Number:
PHS2007-2
Branch:
N/A
Award Year:
2008
Phase:
Phase I
Agency Tracking Number:
NS056510
Solicitation Topic Code:
N/A
Small Business Information
MEDIGENIX, LLC
MEDIGENIX, LLC, 21315 HILLTOP ST, SOUTHFIELD, MI, 48034
Hubzone Owned:
Y
Woman Owned:
Y
Socially and Economically Disadvantaged:
Y
Duns:
605939805
Principal Investigator
 () -
Business Contact
Phone: (248) 353-4900
Email: dday@mol-innov.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): This Phase I SBIR proposal will investigate the feasibility of using a unique fusion tag system for the high level expression and purification of native human and mouse neuroserpin. Our collaborators at the University o f Michigan have shown in animal models that the neuroserpin protein appears to have profound neuroprotective effects and therefore has great therapeutic potential in the treatment of ischemic stroke. To date, the material has proven to be exceeding difficu lt to obtain in the quantities necessary to conduct more detailed animal studies and the lack of the reagent has created a bottleneck in the development of more detailed and elaborate studies. We propose to produce the neuroserpin protein reagents in a sta ble insect cell line on a large scale and to subsequently test them in an in vitro assay for functional biological activity. These proteinase inhibitors will form the basis of an eventual Phase II study where they will be used therapeutically in a mouse st roke model. This model will allow for the evaluation of their efficacy in the attenuation of neuronal cell death associated with induced stroke. If successful, the new fusion tag system will also have a broader scope than just this proposal. This new tag w ill be very be generalized and have the potential to be commercialized for the purification of other important academic and industrial protein based reagents. Neuroserpin protein represents a promising new therapeutic in the treatment of ischemic stroke, w hich is the second leading cause of death and disability throughout the world. Medigenix LLC proposes to develop a new method for the production of this protein on a large scale. This methodology may also prove useful in many other protein-based therapeuti cs in the future.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government